Long/short healthcare hedge fund focused on SMID cap biotechs | Consultants and VCs in early-stage biotech/LifeSci companies | Tweets are not investment advice
$BPMC $DCPH #ASH19 They can't say the same thing for ICB in GIST pts with no such cases. Not to mention G1/2 cog effects showing up in 25mg,50mg pts so early on; hence, the FDA's request to see VOYAGER data before review. Moving away from ava and onto 263 is just a matter of time
$BPMC Give credit where it's due to $DB analyst Konstantinos Aprilakis on catalyst call of the year. Not only did he call out ava's cog tox but also deduced LIMK1 inhibition as the culprit with some rare sellside scientific DD. One of 2019's best contrarian research pieces
$BPMC $DCPH #ASH19 By all accounts mgmt sounded defeated on the call. Will be hard for FDA to approve a drug without a molecular basis for its cognitive effects. 263 is a concession as it doesn't cross BBB. While they can explain away ICB event in SM as due to thrombocytopenia...
@cycleflyer LIMK1 inhibition has a cumulative effect. If you’re already seeing G3 cog tox at low dose so early on you can expect that pts on chronic tx will develop irreversible cog tox. Ava isn’t a viable tx options in ISM or even broader GIST